Send to

Choose Destination
Diabetes Technol Ther. 2019 Dec 19. doi: 10.1089/dia.2019.0400. [Epub ahead of print]

Prospective analysis of the impact of commercialised hybrid closed-loop system on glycaemic control, glycaemic variability and patient-related outcomes in children and adults: a focus on superiority over predictive low glucose suspend technology.

Author information

University Hospital Complex Badajoz, 54390, Avda. Elvas s/n, Badajoz, Spain, 06006;
University Hospital Complex Badajoz, 54390, Badajoz, Spain;
University Hospital Complex Badajoz, 54390, Badajoz, Extremadura, Spain;
Complejo Hospitalario Virgen de la Macarena, 16582, Sevilla, Andalucía, Spain;
University Hospital Complex Badajoz, 54390, Badajoz, Extremadura, Spain;



Automatization of insulin delivery by closed-loop systems represents a major step in type 1 diabetes (T1D) management. The aim of this study was to analyse the effect of the commercialised hybrid closed-loop system, the MiniMed 670G system, on glycaemic control, glycaemic variability and patient satisfaction.


A prospective study, including T1D patients consecutively starting on the 670G system in one adult and two paediatric hospitals, was performed. Baseline and 3-month visits were documented. Two weeks of data from the system were downloaded. Glycaemic variability measures were calculated. Adults and adolescents completed a set of questionnaires (Gold and Clarke scores, Hypoglycemia Fear Survey, Diabetes Quality of Life, Diabetes Treatment Satisfaction, Diabetes Distress Scale, Pittsburgh Sleep Quality Index).


58 patients were included (age: 28±15 years (7-63), <18 years-old: 38% (n=22), 59% (n=34) females, previous use of SAP-PLGS: 60% (n=35)). HbA1c was reduced from 57±10 to 53±7 mmol/l (7.4±0.9% to 7.0±0.6%) (p<0.001) and time in range 70-180 mg/dl was increased from 63.0±11.4% to 72.7±8.7% (p<0.001). In patients with high baseline hypoglycaemia risk, time <54 mg/dl and <70 mg/dl were reduced from 0.9±1.1% to 0.45±0.7% (p=0.021) and from 3.3±2.8% to 2.1±2.1% (p=0.019), respectively. Glycaemic variability measures improved. Time in Auto Mode was 85±17%, the number of Auto Mode exits was 0.6±0.3/day and the number of alarms was 8.5±3.7/day. Fear of hypoglycaemia, diabetes quality of life, diabetes treatment satisfaction and diabetes distress improved, while the percentage of patients with poor sleep quality was reduced. The discontinuation rate was 3%.


The commercialised hybrid closed-loop system improves glycaemic control and glycaemic variability in children and adults, reducing the burden of living with T1D.


Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center